Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094247 | 0.94 | SCN5A (0.45) | MAOBAOC3L3MBTL1KCNH2SCN10A | |
| SCHEMBL1045849 | 0.83 | MAOB (0.45) | MAOBAOC3L3MBTL1MAPTEPHX2 | |
| SCHEMBL1044621 | 0.81 | MAOB (0.47) | MAOBAOC3L3MBTL1MAPTEPHX2 | |
| SCHEMBL4707838 | 0.80 | NQO1 (0.47) | MAOBL3MBTL1MAPTTSHRLMNA | |
| SCHEMBL254957 | 0.80 | MAPT (0.56) | MAOBAOC3L3MBTL1MAPTEPHX2 | |
| SCHEMBL2005052 | 0.79 | SYK (0.41) | MAOBMRGPRX4KCNH2SCN10AGPR3 | |
| SCHEMBL1044641 | 0.79 | EPHX2 (0.47) | MAOBAOC3L3MBTL1EPHX2MRGPRX4 | |
| SCHEMBL11378368 | 0.79 | NQO1 (0.40) | MAPTALDH1A1TSHRKDM4E | |
| SCHEMBL1046561 | 0.78 | EPHX2 (0.46) | MAOBAOC3L3MBTL1EPHX2MRGPRX4 | |
| SCHEMBL8778595 | 0.78 | EPHX2 (0.46) | MAOBAOC3L3MBTL1EPHX2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8247431-B2 | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2144898-B1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007043542-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-19 | — | — | WO | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOB 1633/4885AOC3 344/4885L3MBTL1 734/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOB 2140/4885AOC3 259/4885L3MBTL1 1931/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | MAOB 53/4885AOC3 483/4885L3MBTL1 2576/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | MAOB 1907/4885AOC3 97/4885L3MBTL1 818/4885 |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, CAT, DNPH1 | MAOB 393/4885AOC3 625/4885L3MBTL1 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.